Diagnosis and management of cholangiocarcinoma

Dalbir S. Sandhu, Lewis Rowland Roberts

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cholangiocarcinoma (CC) is a rare yet frequently fatal tumor that causes significant morbidity and mortality due to late presentation. Radiology is the mainstay of CC diagnosis; however, advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Although surgical resection is the standard of care for resectable CC, liver transplantation has shown excellent results in selected patients. The use of chemotherapy and radiotherapy are currently limited by marginal response rates, toxicity, and biliary complications. Locally ablative therapies in the form of transcatheter arterial chemoembolization and radioembolization are under investigation. Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalCurrent Gastroenterology Reports
Volume10
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Cholangiocarcinoma
Vascular Endothelial Growth Factor Receptor-2
Genomic Instability
Therapeutics
Standard of Care
Oncogenes
Epidermal Growth Factor Receptor
Radiology
Liver Transplantation
Immunotherapy
Interleukin-6
Radiotherapy
Inflammation
Morbidity
Drug Therapy
Mortality
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Diagnosis and management of cholangiocarcinoma. / Sandhu, Dalbir S.; Roberts, Lewis Rowland.

In: Current Gastroenterology Reports, Vol. 10, No. 1, 2008, p. 43-52.

Research output: Contribution to journalArticle

@article{a2447a8598de49c78af324bf99448fea,
title = "Diagnosis and management of cholangiocarcinoma",
abstract = "Cholangiocarcinoma (CC) is a rare yet frequently fatal tumor that causes significant morbidity and mortality due to late presentation. Radiology is the mainstay of CC diagnosis; however, advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Although surgical resection is the standard of care for resectable CC, liver transplantation has shown excellent results in selected patients. The use of chemotherapy and radiotherapy are currently limited by marginal response rates, toxicity, and biliary complications. Locally ablative therapies in the form of transcatheter arterial chemoembolization and radioembolization are under investigation. Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC.",
author = "Sandhu, {Dalbir S.} and Roberts, {Lewis Rowland}",
year = "2008",
doi = "10.1007/s11894-008-0008-9",
language = "English (US)",
volume = "10",
pages = "43--52",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of cholangiocarcinoma

AU - Sandhu, Dalbir S.

AU - Roberts, Lewis Rowland

PY - 2008

Y1 - 2008

N2 - Cholangiocarcinoma (CC) is a rare yet frequently fatal tumor that causes significant morbidity and mortality due to late presentation. Radiology is the mainstay of CC diagnosis; however, advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Although surgical resection is the standard of care for resectable CC, liver transplantation has shown excellent results in selected patients. The use of chemotherapy and radiotherapy are currently limited by marginal response rates, toxicity, and biliary complications. Locally ablative therapies in the form of transcatheter arterial chemoembolization and radioembolization are under investigation. Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC.

AB - Cholangiocarcinoma (CC) is a rare yet frequently fatal tumor that causes significant morbidity and mortality due to late presentation. Radiology is the mainstay of CC diagnosis; however, advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Although surgical resection is the standard of care for resectable CC, liver transplantation has shown excellent results in selected patients. The use of chemotherapy and radiotherapy are currently limited by marginal response rates, toxicity, and biliary complications. Locally ablative therapies in the form of transcatheter arterial chemoembolization and radioembolization are under investigation. Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC.

UR - http://www.scopus.com/inward/record.url?scp=51549121090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549121090&partnerID=8YFLogxK

U2 - 10.1007/s11894-008-0008-9

DO - 10.1007/s11894-008-0008-9

M3 - Article

C2 - 18417042

AN - SCOPUS:51549121090

VL - 10

SP - 43

EP - 52

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -